title: MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy.
abstract: OBJECTIVE
  To investigate the positive biopsy rate of MRI-guided biopsy (MR-GB) in a routine clinical setting, identify factors predictive for positive biopsy findings and to report about the clinical significance of the diagnosed tumors.
  
  
  METHODS
  Patients with at least one negative trans-rectal-ultrasound-guided biopsy (TRUS-GB), persistently elevated or rising serum prostate specific antigen (PSA) and at least one lesion suspicious for PCa on diagnostic 1.5 Tesla endorectal coil MRI (eMR) were included. Biopsies were carried out using a 1.5 Tesla MRI and an 18 G biopsy gun. Clinical information and biopsy results were collected; logistic regression analysis was carried out. Definite pathology reports of patients with diagnosis of PCa and subsequent radical prostatectomy (RP) were analyzed for criteria of clinical significance.
  
  
  RESULTS
  One hundred patients were included, mean number of previous biopsies was 2 (range 1-9), mean PSA at time of biopsy was 11.7 ng/ml (1.0-65.0), and mean prostate volume was 46.7 ccm (range 13-183). In 52/100 (52.0%) patients, PCa was detected. Out of 52 patients, 27 patients with a positive biopsy underwent RP, 20 patients radiation therapy, and 5 patients active surveillance. In total, 80.8% of the patients revealed a clinically significant PCa. In univariate regression analysis, only serum PSA levels were predictive for a positive biopsy result. Number of preceding negative biopsies was not associated with the likelihood of a positive biopsy result.
  
  
  CONCLUSIONS
  MR-GB shows a high detection rate of clinically significant PCa in patients with previous negative TRUS-GB and persisting suspicion for PCa.
authors.affiliation: Department of Radiology, Comprehensive Cancer Center (CCC) Tübingen, Eberhard-Karls-Universität, Tübingen, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Roethke
authors.forename: A G
authors.initials: AG
authors.lastname: Anastasiadis
authors.forename: M
authors.initials: M
authors.lastname: Lichy
authors.forename: M
authors.initials: M
authors.lastname: Werner
authors.forename: P
authors.initials: P
authors.lastname: Wagner
authors.forename: S
authors.initials: S
authors.lastname: Kruck
authors.forename: Claus D
authors.initials: CD
authors.lastname: Claussen
authors.forename: A
authors.initials: A
authors.lastname: Stenzl
authors.forename: H P
authors.initials: HP
authors.lastname: Schlemmer
authors.forename: D
authors.initials: D
authors.lastname: Schilling
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001707:Biopsy, Needle / Q000379:methods; D002277:Carcinoma / Q000097:blood / Q000000981:diagnostic imaging / Q000473:pathology*; D015331:Cohort Studies; D005188:False Negative Reactions; D006801:Humans; D053783:Magnetic Resonance Imaging, Interventional / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000000981:diagnostic imaging / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000473:pathology*; D018084:Ultrasonography, Interventional / Q000379:methods*
chemical_list: D017430:Prostate-Specific Antigen